Ketoconazole Levonorgestrel

Noninterfering cyclosporin, ethinyl estradiol, ketoconazole, levonorgestrel, rapamycin, tacrolimus, tenidap, tetrahydrocoitisone... 

Drugs that may affect repaglinide include CYP 450 inhibitors (eg, clarithromycin, erythromycin, ketoconazole, miconazole), CYP 450 inducers (eg, barbiturates, carbamazepine, rifampin), beta blockers, calcium channel blockers, chloramphenicol, corticosteroids, coumarins, estrogens, gemfibrozil, isoniazid, itraconazole, levonorgestrel and ethinyl estradiol, MAOIs, nicotinic acid, NSAIDs, oral contraceptives, phenothiazines, phenytoin, probenecid, salicylates, simvastatin, sulfonamides, sympathomimetics, thiazides and other diuretics, and thyroid products. 

Pfizer, the marketing authorization holder of ziprasidone, has promoted several pharmacokinetic studies. Oral contraceptives (ethinylestradiol 30 pg/day plus levonorgestrel 150 pg/day) (34), lithium 900 mg/day (35), ketoconazole 400 mg/day (36), and carbamazepine (100-400 mg/day)... 

---